Cytokine Release Syndrome– tag –
-
Real-World Data Evaluates Incidence and Management of Cytokine Release Syndrome and Neurotoxicity Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel CAR-T Cell Therapy Across 87 U.S. Centers
PubMed (Center for International Blood and Marrow Transplant Research) USA Overview The Center for International Blood and Marrow Transplant Research (CIBMTR) conducted a real-world data analysis of 927 B-cell malignancy patients across ... -
Advanced CAR-T/NK Therapies for Solid Tumors: iPSC-Derived CAR-NK Cells Show Promise in Efficacy and Safety
Oncodaily Global Overview In solid tumor treatment, IL-15 armed GPC3 CAR-T cells demonstrated promising early data, with cytokine release syndrome (CRS) managed by an inducible caspase-9 switch. Notably, iPSC-derived IL-15 incorporated C... -
Hospital Capacity, Not Just Manufacturing, Identified as True Bottleneck for CAR-T Therapy Commercialization
Chivanta Unknown Overview The greatest challenge in commercializing CAR-T cell therapies is not solely manufacturing capacity but also the hospital infrastructure and the overall treatment process. Clinical operational bottlenecks, speci...
1